Page last updated: 2024-09-02

fingolimod hydrochloride and ibudilast

fingolimod hydrochloride has been researched along with ibudilast in 1 studies

Compound Research Comparison

Studies
(fingolimod hydrochloride)
Trials
(fingolimod hydrochloride)
Recent Studies (post-2010)
(fingolimod hydrochloride)
Studies
(ibudilast)
Trials
(ibudilast)
Recent Studies (post-2010) (ibudilast)
2,7711572,0622003197

Protein Interaction Comparison

ProteinTaxonomyfingolimod hydrochloride (IC50)ibudilast (IC50)
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)0.4693
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)1.71
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)0.239
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.166

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dolgin, E1

Other Studies

1 other study(ies) available for fingolimod hydrochloride and ibudilast

ArticleYear
Therapies: Progressive steps.
    Nature, 2016, 11-30, Volume: 540, Issue:7631

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; Benzyl Compounds; Blood-Brain Barrier; Clinical Trials as Topic; Disease Progression; Dogs; Drug Approval; Fingolimod Hydrochloride; Hope; Humans; Male; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Piperidines; Precision Medicine; Pyridines; Rituximab; Thiazoles; Ubiquinone; United States; United States Food and Drug Administration

2016